AC676 — Investigational Agent
BTK Degrader · Phase 1 · Accutar Biotechnology
Mechanism of Action
Oral chimeric degrader that hijacks cereblon to ubiquitinate and degrade BTK, eliminating both wild-type and inhibitor-resistant (C481) BTK and thereby abrogating scaffolding as well as kinase functions of BTK.
Investigational Indications
- Relapsed/refractory B-cell malignancies
- Chronic lymphocytic leukemia